Human Anti-rabies Vaccine Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Human Anti-rabies Vaccine Market is segmented By Product Type (Vero Cell Rabies Vaccine, Baby Hamster Kidney (BHK) Cells, Chick Embryo Cell Rabies Vaccine, Others), By Usage (Post-Exposure Prophylaxis (PEP), Pre-Exposure Vaccination (PEV)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), and By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Human Anti-rabies Vaccine Market reached US$ 1103.5 million in 2023 and is expected to reach US$ 1541.4 million by 2031, growing at a CAGR of 5.7% during the forecast period 2024-2031.

Domestic dogs are the most common reservoir of the virus, with more than 99% of human deaths caused by dog-mediated rabies. The virus is transmitted in the saliva of rabid animals and generally enters the body via infiltration of virus-laden saliva from a rabid animal into a wound or by direct exposure of mucosal surfaces to saliva from an infected. Rabies is a 100% vaccine-preventable disease.

For instance, according to WHO, for both PEP and PrEP, vaccines can be administered by either intra-dermal (ID) or intra-muscular (IM) routes. Previously WHO-recommended rabies vaccine schedules for IM administration remain acceptable, but the new ID administration schedules recommended by the WHO Strategic Advisory Group of Experts (SAGE) offer advantages through savings in costs, doses, and time. While deaths can be averted by human vaccination, this intervention alone will never eliminate the disease, and costs will only escalate over time. Investment in eliminating the risk of rabies at its source, dogs is the most cost-effective measure.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of rabies cases

The demand for the global human anti-rabies vaccine market is driven by multiple factors. The rising prevalence of rabies cases propels the market growth. For instance, according to an article published by WHO in June 2024, rabies is present on all continents except Antarctica. Globally there are an estimated 59,000 deaths from rabies annually; however, due to underreporting, documented case numbers often differ from the estimate. 

Rabies is a neglected tropical disease (NTD) that predominantly affects marginalized populations. Although effective human vaccines and immunoglobulins exist for rabies, these are often inaccessible or unaffordable to those in need. Over 29 million people worldwide receive human rabies vaccine annually. The global cost of rabies is estimated to be around US$ 8.6 billion per year including lost lives and livelihoods, medical care and associated costs, as well as uncalculated psychological trauma. 

Low awareness of the need to seek health care after a dog bite claims the lives of more than 55,000 people each year, mostly in Asia and Africa. India is endemic for rabies and accounts for 36% of the world’s rabies deaths. The true burden of rabies in India is not fully known; although as per available information, it causes 18 000-20 000 deaths every year. About 30-60% of reported rabies cases and deaths in India occur in children under the age of 15 years as bites that occur in children often go unrecognized and unreported.

Restraints

Factors such as lack of awareness among people are expected to hamper the market. Due to a lack of awareness among people, there was a sudden spike in rabies cases and dog-bite-induced deaths in India and many other countries in recent times. Rising cases were reported by the National Institute for Communicable Diseases (NICD) as compared to earlier years.

Market Segment Analysis

The global human anti-rabies vaccine market is segmented based on product type, usage, end-user, and region.

The vero cell vaccine accounted for approximately 48.9% of the global human anti-rabies vaccine market share

The vero cell vaccine segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research would drive this market. 

Purified vero cell rabies vaccine is composed of purified vero cell rabies vaccine which is indicated to prevent and treat rabies before and after exposure to the virus. This vaccine is made by growing the rabies virus in these cells and then purifying it to remove unwanted substances. The purified virus is then inactivated, meaning it can no longer cause disease but still stimulate an immune response. Pre-exposure vaccination is for travelers, those in high-risk occupations, and children living in rabies-prone areas. Post-exposure prophylaxis refers to prompt wound management and vaccination. This vaccine is prepared from the Pitman-Moore strain of the rabies virus grown in vero cells.

For instance, in May 2024, in Japan, HEP-Flury, the viral strain, used as a human rabies vaccine, has historically been propagated in primary fibroblast cells derived from chicken embryos. In the present study, to reduce the cost and labor of vaccine production. Comparison among 18 recombinant HEP strains constructed by reverse genetics and vesicular stomatitis viruses pseudotyped with RABV glycoproteins indicated that the substitution P(L115H) in the phosphoprotein and G(S15R) in the glycoprotein improved viral propagation in HEP-10V, while in HEP-30V, G(V164E), G(L183P), and G(A286V) in the glycoprotein enhanced entry into Vero cells. The obtained recombinant RABV strain, rHEP-PG4 strain, with these five substitutions, is a strong candidate for the production of the human rabies vaccine.

Market Geographical Share

Asia-Pacific accounted for approximately 47.9% of the global human anti-rabies vaccine market share 

Asia-Pacific region is expected to hold the largest market share over the forecast period. The rising incidence of rabies, government initiatives and funding, and growing awareness among people, in this region, help to propel the market.

 For instance, in June 2024, Gavi, the Vaccine Alliance, in collaboration with partners, announced support for human rabies vaccines for post-exposure prophylaxis (PEP) as part of routine immunization. Eligible countries are receiving guidance on how to access these vaccines under Gavi's cofinancing policy. The first round of applications will be accepted by mid-July 2024. Ninety-five percent of human rabies deaths occur in Africa and Asia, most often in marginalized communities that lack access to care.

This development complements ongoing global efforts of the Zero by 30 campaign, led by United Against Rabies partners including the Food and Agriculture Organization (FAO), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH, formerly OIE) with the goal of eliminating dog-mediated human rabies by 2030.

Market Segmentation

By Product Type

• Vero Cell Rabies Vaccine
• Baby Hamster Kidney (BHK) Cells
• Chick Embryo Cell Rabies Vaccine
• Others

By Usage

• Post-Exposure Prophylaxis (PEP)
• Pre-Exposure Vaccination (PEV)

By End-User

• Hospitals
• Specialty Clinics
• Others

By Region

• North America 
• The U.S.
• Canada
• Mexico 
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe 
• South America
• Brazil
• Argentina
• Rest of South America 
• Asia-Pacific 
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the global human anti-rabies vaccine market include Sanofi, Bavarian Nordic, Novartis, Yisheng Group, Serum Institute of India, Chiron Behring Vaccines Pvt. Ltd., Zuventus Healthcare, CPL Biologicals, GlaxoSmithKline, and Zydus among others.

Key Developments

• On November 14, 2022, according to an article published in the virology journal, scientists developed a novel mRNA-based vaccine candidate against the rabies virus. The vaccine induces a strong antibody response and exhibits high protective efficacy against lethal rabies infection in mice and dogs. 

Why Purchase the Report?

• To visualize the global human anti-rabies vaccine market segmentation based on product type, usage, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global human anti-rabies vaccine market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The human anti-rabies vaccine market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies